Luminate

ALG-1001: Turning off the machinery of angiogenesisALG-1001 (Luminate, Allegro Ophthalmics) has a number of different mechanisms of action that benefit patients chronically treated with anti-vascular endothelial growth factor drugs and those who are treatment naïve.
Investigational drug Luminate targets integrin receptorsAnti-integrin therapy is a promising new approach in the treatment of vitreoretinal disease. The first drug in this class, Allegro Ophthalmics’ Luminate, is in Phase 2 clinical trials for several indications, including wet age-related macular degeneration, diabetic macular edema, non-proliferative diabetic retinopathy, and vitreomacular traction.
Integrin peptide yields positive outcomes for VMA, VMT in phase II trialA new possible therapy for vitreomacular adhesion and vitreomacular traction had positive results in a phase II trial.
Integrin peptide trials continue for wet AMD, DME, other pathologiesThe first drug in the new class integrin peptide therapy continues to show continued efficacy and safety in various clinical trials.